Oncolytic viruses (OVs) are emerging as a revolutionary cancer treatment. By partnering with an experienced CDMO, you can overcome the complexities of OV production and deliver high-quality therapies. Delve into the exciting potential of OVs, as well as the critical role of cell and virus seed banks in their development, and discover key considerations for establishing cell and virus banks for OV production.
The pharmaceutical industry faces a lack of expertise in antibiotic development and requires advanced filling capabilities and scalability. Learn how three companies collaborated to develop a new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.
mRNA technologies played a crucial role in the fight against COVID-19, and new programs are being developed to revolutionize their development and production. Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies.
Learn more about our global capabilities in Nucleic Acid (xRNA:LNP), AAV, Lentivirus, Microbiome and Fill-Finish. We offer end-to-end GMP manufacturing under one roof through an integrated supply chain from upstream to fill-finish. With facilities in Europe and North America, ReciBioPharm is ready to support your discovery, clinical and commercial cell and gene therapy ATMPs.
